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Abstract
The complex pathology of B. pertussis infection is due to multiple virulence factors having disparate effects on different cell types.
We focused our investigation on the ability of B. pertussis to modulate host immunity, in particular on the role played by
adenylate cyclase toxin (CyaA), an important virulence factor of B. pertussis.Asatool,weusedhumanmonocytederiveddendritic
cells (MDDC), an ex vivo model useful for the evaluation of the regulatory potential of DC on T cell immune responses. The work
compared MDDC functions after encounter with wild-type B. pertussis (BpWT) or a mutant lacking CyaA (BpCyaA2), or the
BpCyaA2 strain supplemented with either the fully functional CyaA or a derivative, CyaA*, lacking adenylate cyclaseactivity. As a
first step, MDDC maturation, cytokine production, and modulation of T helper cell polarization were evaluated. As a second step,
engagement of Toll-like receptors (TLR) 2 and TLR4 by B. pertussis and the signaling events connected to this were analyzed.
These approaches allowed us to demonstrate that CyaA expressed by B. pertussis strongly interferes with DC functions, by
reducing the expression of phenotypic markers and immunomodulatory cytokines, and blocking IL-12p70 production. B.
pertussis-treated MDDC promoted a mixed Th1/Th17 polarization, and the activity of CyaA altered the Th1/Th17 balance,
enhancing Th17 and limiting Th1 expansion. We also demonstrated that Th1 effectors are induced by B. pertussis-MDDC in the
absence of IL-12p70 through an ERK1/2 dependent mechanism, and that p38MAPK is essentialforMDDC-drivenTh17expansion.
The data suggest that CyaA mediates an escape strategy for the bacterium, since it reduces Th1 immunity and increases Th17
responses thought to be responsible, when the response is exacerbated, for enhanced lung inflammation and injury.
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Introduction
Bordetella pertussis is a Gram-negative coccobacillus that causes
whooping cough, a respiratory disease representing a severe, life-
threatening illness in infants and children and a significant cause of
morbidity in adolescents and adults [1–3]. The incidence of
pertussis is increasing, even in countries with high vaccine
coverage where immunity to pertussis is waning and a growing
number of vaccinated adults have lost protection. Consequently,
Bordetella infection is once again on the rise as a public health
threat [2,4]. Many aspects of pertussis pathogenesis and the
mechanisms involved in protection from the disease are not fully
understood, a situation complicated by the large number of
virulence factors expressed by B. pertussis that exert disparate
effects on different cell types [5,6].
Adenylate cyclase toxin (CyaA) is secreted by B. pertussis and
binds to the cell surface receptor CD11b/CD18 aMb2 integrin
which is expressed on innate immune cells, including macrophages
and dendritic cells (DC) [7]. Within cells, CyaA is able to disrupt
host cellular functions by increasing the intracellular cyclic AMP
(cAMP) concentration [8–10]. CyaA is able to suppress host
antibactericidal activity by inhibiting chemotaxis, phagocytosis,
superoxide production and expression of pro-inflammatory
cytokines, such as TNF-a and IL-12p70, in monocyte/macro-
phages, neutrophils and DC [11–16], thereby promoting bacterial
colonization and persistence [17,18]. Moreover CyaA is also able
to induce apoptosis in macrophages [19,20].
DC are major players in innate and adaptive immunity, as they
express repertoires of pathogen-recognition receptors that recog-
nize specific molecular signatures of pathogens and trigger
antimicrobial defense responses. Activation of DC leads to the
production of cytokines and other immune mediators promoting
the development of specific T helper (Th) responses that play a
critical role in host protective immunity against infectious agents
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8734[21,22]. We have previously shown that B. pertussis triggers
maturation of human monocyte-derived (MD)DC that efficiently
perform antigen presentation and, although unable to produce IL-
12p70, drive the development of Th1 immunity [23]. In a
subsequent study we demonstrated that IL-12p70 is inhibited
through a block of IL-12p35 expression [15].
In this study we focused on the mechanisms that B. pertussis
employs to escape host immune responses and the role played by
CyaA. The experimental approach involved the analysis of T cell
responses induced by human MDDC cultured with wild type B.
pertussis (BpWT) or an isogenic mutant strain lacking CyaA,
BpCyaA2 [18], and by using fully functional recombinant CyaA
or a derivative lacking adenylate cyclase activity, CyaA*, to
complement the BpCyaA2 strain [24,25]. These approaches
allowed us to demonstrate the induction by B. pertussis of MDDC
promoting a mixed Th1/Th17 polarization and to clarify the role
played by the p38 and ERK1/2 mitogen-activated protein kinases
(MAPK) in this process. The data shed light on the role played by
CyaA in subverting host immune responses by enhancing Th17
immunity and limiting the induction of Th1 effectors.
Results
B. pertussis CyaA Inhibits MDDC Maturation and Cytokine
Production
After the encounter with a pathogen, the differentiation
program of MDDC starts with the modification of surface markers
expression [21,22]. In preliminary experiments MDDC were
treated with BpWT or with BpCyaA2 and the ability of MDDC
to internalize the two types of bacteria and the intracellular
survival of internalized bacteria were measured, as reported in a
previous study for BpWT [23]. The BpCyaA2 strain behaved
similarly to BpWT, both strains had a comparable low capability
to be internalized by- and to survive in- MDDC (data not shown).
Phenotypic maturation of MDDC treated with BpWT or with
BpCyaA2 was then assessed. In order to restore adenylate cyclase
activity to BpCyaA2, recombinant CyaA was simultaneously
administered and a genetically inactivated toxin, lacking adenylate
cyclase enzymatic activity, CyaA*, was used as a control. In
previous studies we defined the optimal bacteria:MDDC ratio to
induce MDDC maturation and functions [23] and here, in
preliminary experiments, we finely titrated CyaA and CyaA* doses
in MDDC cultures. We found that a 50 ng/ml dose of CyaA was
optimal to maximize the induction of intracellular cAMP and to
minimize the induction of apoptosis (data not shown). Table 1
summarizes MDDC surface expression of the co-stimulatory
molecule CD80 and the maturation markers CD83 and CD38
induced by the bacteria. Both B. pertussis strains induced significant
up-regulation of phenotypic markers with respect to untreated
MDDC. The BpCyaA2strain was able to induce significantly
higher levels of CD80 and CD83 expression compared to BpWT
strain (p,0.05), confirming and extending previous data [15,23].
The expression of CD38, a newly described maturation marker
involved in the regulation of IL-12p70 [26,27], was also higher in
BpCyaA2 -treated MDDC compared to BpWT -treated MDDC
(p,0.05). Expression of maturation markers declined to levels
similar to those induced by BpWT when CyaA was added to
MDDC cultured with BpCyaA2, but not when CyaA* was used
(Table 1). No relevant modification of expression was found when
the toxins were used alone to stimulate MDDC, indicating that
any LPS contamination of the recombinant CyaA proteins was
very low, confirming the results of the LAL test [24,25], and not
detectable even using MDDC maturation as a functional
biological assay.
These phenotypic data revealed that CyaA was responsible for
the inhibition of CD80, CD83 and CD38 expression in B. pertussis
-treated MDDC, thereby reducing the overall degree of DC
maturation.
DC maturation leads to the production of several regulatory
cytokines pivotal in driving T helper (Th) cell polarization. Here,
we analyzed the role of CyaA in modulation of cytokine
production by MDDC in the presence of B. pertussis. BpWT strain
was unable to induce IL-12p70 secretion, while BpCyaA2
promoted the release of statistically significant levels of IL-12p70
(P=0.01) (Figure 1), confirming previous data [15,23]. In order to
confirm that CyaA was responsible for IL-12p70 inhibition,
MDDC were cultured with BpCyaA2 in the presence of CyaA or
CyaA*. Addition of CyaA strongly and significantly inhibited IL-
12p70 production with respect to BpCyaA2- and to BpCyaA2+
CyaA* -treated MDDC. CyaA* addition did not significantly
affect IL-12p70 induced by BpCyaA2 -treated MDDC (Figure 1).
The combination of IL-23, IL-6 and IL-1b has been shown to
be crucial in driving the differentiation and expansion of Th17
cells, a recently described Th subset involved in infections and
autoimmune disorders [28–30]. In this context, we found that B.
pertussis induced IL-23 as well as IL-1b and IL-6 in MDDC




b (% of positive cells) CD38
b (MFI)
BpWT 4464( 2 . 3 60.2)
c 3966( 2 . 3 60.4)
c 2362( 2 . 1 60.2)
c
BpCyaA2 76612 (2.260.3)
c,d,e 4665( 2 . 6 60.8)
c,d,e 4265( 2 . 6 60.4)
c,d,e
BpCyaA2+CyaA 41610 (2.660.2)
c 1964( 2 . 4 60.1)
c 1964( 2 . 5 60.4)
c
BpCyaA2+CyaA* 87620 (2.460.3)
c 4069( 2 . 5 60.9)
c 4069( 2 . 6 60.8)
c
none 2062( 2 . 1 60.3) 461 (2.160.6) 1162( 2 . 4 60.3)
CyaA 2163( 2 . 5 60.1) 663 (2.060.2) 961 (2.260.1)
CyaA* 2264( 2 . 2 60.2) 261 (2.760.7) 961 (2.160.3)
aMDDC were treated with indicated stimuli for 48 h and analyzed for indicated surface markers associated with the mature phenotype. Isotype-matched antibodies
were used as negative controls and the values are shown in brackets.
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compared to those induced by BpCyaA2 (P=0.002). The
addition of CyaA to BpCyaA2 -treated MDDC significantly
inhibited IL-23 production, while the addition of CyaA* was
ineffective (Figure 1). Moreover, CyaA, either expressed by BpWT
or exogenously added to BpCyaA2, was associated with reduced
IL-1b and IL-6 production, although without statistically signif-
icant differences. Both B. pertussis strains were able to induce high
levels of IL-10 and the addition of CyaA inhibited IL-10 induced
by BpCyaA2 (Figure 1).
When used alone, CyaA and CyaA* did not induce any of the
cytokines tested with the exception of IL-23, produced at very low
levels not significantly different than those from untreated MDDC,
confirming again that any LPS contamination of the proteins was
undetectable (data not shown).
CyaA Modulates Th1/Th17 Polarization Induced by B.
pertussis Treated MDDC
Considering the cytokine profile induced by B. pertussis in
MDDC, we analyzed their capacity to polarize purified T
lymphocytes, and, in particular, the possibility of Th17 induc-
tion/expansion. Figure 2 shows that BpWT -treated MDDC drove
IFNc- and IL-17 -producing Th effector cells. Remarkably, in
view of the findings in the previous section, when T cells were co-
cultured with BpCyaA2 -treated MDDC, a significant decrease of
IL-17 -producing cells was observed, along with a significant
increase of IFNc -producing cells. The addition of CyaA to
BpCyaA2 -treated MDDC reverted the polarization profile to
that induced by BpWT and IL-17 -producing Th cells were
enhanced, while those producing IFNc significantly decreased.
CyaA* did not cause any significant alteration of the polarization
profile induced by BpCyaA2 -treated MDDC (Figure 2). Th2
polarization, assessed by measuring IL-5 release, was significantly
reduced when MDDC were treated with both B. pertussis strains,
with respect to untreated MDDC.
B. pertussis Triggers MyD88 - and Phosphatidyl Inositol 3
Kinase -Dependent Pathways in MDDC
The activation of TLR4 and TLR2 by B. pertussis was
investigated by using TLR2- and TLR4- expressing HEK-293
cells [31]. Figure 3 shows that BpWT and BpCyaA2 were able to
induce a potent activation of TLR2, at levels comparable to
Figure 1. Cytokine production. MDDC were either untreated (none)
or treated with BpWT or BpCyaA2, the latter in the presence or absence
of CyaA and CyaA* (50 ng/ml ) for 48 h. IL-12p70, IL-23, IL-1b, IL-6 and
IL-10 were assessed by ELISA. Values are expressed as mean 6 SE from
nineteen (IL-12p70), eleven (IL-10), six (IL-23, IL-1b and IL-6) indepen-
dent experiments performed with MDDC obtained from different
donors, and expressed as pg/ml of cytokine released. * p,0.05 vs none;
up,0.05 vs BpWT;
{ p,0.05 vs BpCyaA2;
1 p,0.05 vs BpCyaA2+CyaA*.
doi:10.1371/journal.pone.0008734.g001
Figure 2. Th polarization. MDDC either untreated (none) or treated
with BpWT or BpCyaA2 for 48 h were co-cultured with purified T cells
as described in Methods section. On day 12, supernatants were
collected and secreted cytokines were measured by ELISA. Results are
expressed as mean 6 SE of eight independent experiments performed
with MDDC and T cells obtained from different donors. * p,0.05 vs
none; u p,0.05 vs BpWT;
{ p,0.05 vs BpCyaA2.
doi:10.1371/journal.pone.0008734.g002
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induced, but the levels of activation were statistically lower with
respect to the ultra pure E. coli LPS, used as positive control.
The core component of TLR signaling is the activation of an IL-
1-like pathway dependent upon the adapter MyD88, leading to
phosphorylation of mitogen activated protein kinases (MAPK)
such as p38, ERK1/2 and SAPK/JNK, and coupling to the
activation of nuclear factor-kB (NF-kB) [32].
Both B. pertussis strains induced the phosphorylation of p38,
ERK1/2, SAPK/JNK, and IkBa, a process that allows the
activation of the NF-kB complex, in MDDC within 5 minutes
after treatment (Figure 4A). The induction of intracellular MAPK
signaling was further analyzed using inhibitors specific for p38
(SB203580) and ERK1/2 (PD98059) and measuring phenotypic
markers and cytokine release (Figure 4B–C). When MDDC were
treated with either BpWT or BpCyaA2, p38 inhibitor induced a
significant inhibition of all maturation markers, in particular
CD83 (reduced by 90%) (Figure 4B), and almost completely
abrogated IL-12p70, IL-23, IL-1b and IL-10 cytokine production
(Figure 4C). The ERK1/2 inhibitor caused a significant reduction
of CD83 maturation marker (by 45%) in the presence of BpWT
with limited effects on cytokine production. When MDDC were
treated with BpCyaA2, the ERK1/2 inhibitor had no significant
influence on phenotypic maturation but elicited some reduction of
cytokine production, particularly of IL-12p70 (inhibited by 70%).
These results demonstrated that B. pertussis exerted intracellular
effects through both p38 and ERK1/2 activation, with the former
having a prominent influence.
Phosphatidyl inositol 3 kinase (PI3K) is activated in response to
various stimuli, including TLR2 engagement [33], thus, consid-
ering the strong involvement of TLR2 activation by B. pertussis
(Figure 3), we investigated its influence in MDDC activation
induced by B. pertussis by using LY294002, a selective inhibitor of
this kinase. The data obtained showed an anti-inflammatory role
of PI3K. While no major differences were observed in phenotypic
maturation in the presence of either BpWT or BpCyaA2
(Figure 4B), this inhibitor caused strong effects on cytokine
production (Figure 4C), in particular a sharply increased level of
IL-23 production (.100% in the case of BpCyaA2) and IL-1b (by
more than 50% with both strains). Conversely, a clear reduction of
IL-10 levels was obtained under these conditions.
B. pertussis CyaA Blocks the Activation of the
MyD88-Independent Pathway
The TRIF-dependent signaling pathway downstream of TLR4
may be triggered independently of MyD88 and leads to the
phosphorylation of interferon regulatory factor (IRF)3 and
thereafter to the production of IFNb and IFN-inducible genes,
including IRF1 and IRF8. In a previous study we showed that
BpWT blocks the expression of the p35 subunit of IL-12p70
through the inhibition of IRF1 and IRF8 expression due to CyaA-
dependent intracellular cAMP accumulation [15]. Here, we found
that BpCyaA2 induced in MDDC a higher level of IRF3
phosphorylation compared to BpWT (Figure 5) and we confirmed
that BpWT strongly inhibited the expression of IRF1 and IRF8.
The addition of CyaA to BpCyaA2-treated MDDC was
responsible for the inhibition of both IRF1 and IRF8 expression
(not shown).
p38 and ERK1/2 MAPK Regulate the Induction of Th17
and Th1 Polarization
To evaluate the contribution of activation pathways to the
capacity of MDDC to polarize Th responses, we performed
experiments where MDDC were treated with the two Bordetella
strains in the presence of kinase inhibitors and then used to
polarize purified T cells (Figure 6). When the capacity of Bordetella -
treated MDDC to polarize a Th1 response was analyzed by
measuring IFNc, no specific effects were observed by using the
p38 inhibitor, even though p38 inhibition caused a drastic
reduction of all the cytokines measured in MDDC (Figure 4).
The use of ERK1/2 inhibitor clearly and significantly reduced
IFNc production by co-cultured T cells either when MDDC were
treated with BpWT or BpCyaA2. These data indicate that ERK1/
2 -dependent Th1 polarization is induced by B. pertussis indepen-
dently of IL-12p70, which was not induced by BpWT in MDDC.
No specific effect was observed by the use of PI3K inhibitor.
When the capacity to polarize a Th17 response was analyzed
after p38 inhibition, a clear and marked inhibition of IL-17
production by co-cultured T cells (more than 70%) was observed,
either when MDDC were treated with BpWT or BpCyaA2.
When ERK1/2 was inhibited, a significant increase of IL-17
production by co-cultured T cells (by 80%) was observed when
MDDC were treated with BpCyaA2.
PI3K inhibition did not cause any significant modification of IL-
17 production when MDDC were treated with either BpWT or
BpCyaA2.
The capacity to polarize a Th2 response was then analyzed and
we found that p38, ERK1/2 and PI3K inhibition all caused an
enhancement of IL-5 production induced by BpWT- and
BpCyaA2-treated MDDC, although without any statistical
significance as compared to untreated MDDC, suggesting a strong
donor to donor variability in the production of this cytokine.
These results indicate a pivotal role for the ERK1/2 pathway in
the induction of Th1 polarization and the p38 pathway in the
induction of a Th17 response. All the pathways studied are
implicated in the inhibition of the Th2 phenotype.
Discussion
Several studies indicated that B. pertussis infection drives a Th1
immune response, mediated by IFNc production, both in mice [6]
and in humans [34,35]. We recently demonstrated that B. pertussis
induces IL-23 expression in human MDDC and promotes Th1
Figure 3. TLR4 and TLR2 activation. Triggering of TLR4 and TLR2 in
transfected HEK293 cells. HEK293/TLR4/p-Nifty2-SEAP and HEK293/
TLR2/p-Nifty2-SEAP cells were either untreated (none) or treated with
BpWT or BpCyaA2 for 16 h. Positive control (PC) for TLR4 stimulation
was E. coli LPS (0.1 mg/ml) and positive control for TLR2 stimulation was
Pam2CSK4 (0.1 mg/ml). SEAP activity in supernatants of cell cultures was
measured. Data are reported as fold increase of SEAP activity over
untreated values. Mean expression 6 SE of ten independent
experiments is indicated. * p,0.05 vs none; u p,0.05 vs PC.
doi:10.1371/journal.pone.0008734.g003
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8734Figure 4. Analysis of MyD88 -dependent pathway induction. A MDDC were either untreated or treated with BpWT or BpCyaA2.
Phosphorylation of p38, ERK1/2, SAP/JNK and IkB-a was determined at the indicated time-points by Western blot. A single gel was run and blotted to
detect phosphorylated proteins and b tubulin to normalize the results. Data are from one representative out of four independent experiments
performed with MDDC obtained from different donors. B MDDC were treated as in panel A, either in the absence or presence of p38 inhibitor
(SB203580), ERK1/2 inhibitor (PD98059) or PI3K inhibitor (LY294002) for 48 h. Results of seven independent experiments performed with MDDC
obtained from different donors are expressed as the percent of change of maturation markers (CD80, CD83, CD38) with respect to the corresponding
stimulus in the absence of inhibitors. Mean 6 SE of marker expression in MDDC not treated with inhibitors was for BpWT: CD80 (MFI)=4866; CD83
(%)=2366; CD38 (MFI)=1864; for BpCyaA2: CD80 (MFI)=72611; CD83 (%)=3667; CD38 (MFI)=4665. * p,0.05 vs control, calculated from the
raw data. C MDDC were treated as in panels A and B. Results of ten (IL-12p70), eight (IL-23 and IL-10) and 5 (IL-1b) independent experiments
performed with MDDC obtained from different donors, measured by ELISA, are expressed as the percent of change of cytokines with respect to the
corresponding stimulus in the absence of inhibitors. Mean 6 SE of cytokine production (pg/ml) in MDDC not treated with inhibitors was for BpWT: IL-
12p70=060; IL-23=310670; IL-1b =330685; IL-10=20346605; for BpCyaA2: IL-12p70=374643; IL-23=6726140; IL-1b=600687; IL-
10=24776593. * p,0.05 vs control, calculated from the raw data.
doi:10.1371/journal.pone.0008734.g004
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evidence showing that B. pertussis biased the host response toward a
mixed Th1/Th17 phenotype through modulation of MDDC
functions, and identified the CyaA and MAPKs as key players in
this process. Indeed, CyaA limited Th1 and enhanced Th17
responses, and the p38 and ERK1/2 MAPK pathways were
involved in the induction of Th17 and Th1 effectors, respectively.
B. pertussis triggers phenotypic maturation of MDDC [15,23].
Here, we broadened our analysis to CD38. We confirmed that
CD38 expression in MDDC was tightly linked to CD83 and IL-
12p70 production [27]. Indeed, CD38, CD83 and IL-12p70 were
all up-regulated when CyaA was absent (Table 1 and Figure 1).
CD38 exerts pleiotropic activities in immune cells and particularly
in DC [36]. Indeed, besides being functionally involved in CD83
expression and IL-12 p70 induction [27], CD38 also ensures
efficient chemotaxis and transendothelial migration driven by CC
chemokine ligand 21 (CCL21) [26]. Thus, the down regulation
exerted by CyaA on CD38 functions can be considered as a
possible escape mechanism adopted by the bacterium to hamper
the host immune response.
Endogenous CyaA expressed by BpWT, or exogenously added to
BpCyaA2 -treated MDDC, limited the production of the cytokines
analyzed. In particular, IL-23 and IL-1b were strongly reduced and
IL-12p70 completely abrogated. MDDC treated with BpWT
induced a Th1 polarized response, characterized by the production
of high IFNc levels (Figure 2). These results were in agreement with
our previous studies [15,23] and confirmed that B. pertussis induces
in MDDC the expression of Th1 promoting factor(s) other than IL-
12p70. As expected, BpCyaA2 -treated MDDC were stronger
inducers of Th1 polarization than BpWT -treated MDDC
(Figure 2), due presumably to the action of IL-12p70.
The relevance of IL-17 activities in response to Bordetella infection
has been pointed out in mice [37–39], and in humans [40,41]. The
present study demonstrated that Th17 polarization was induced ex
vivo by B. pertussis -treated MDDC. Interestingly, IL-17 induced in T
cells by BpWT -treated MDDC was greater than that from
BpCyaA2 -treated MDDC, indicating that CyaA promoted IL-17
production by T cells. However, the capacity to induce a stronger
Th17 polarization appeared to be unrelated to the levels of Th17
promoting cytokines, such as IL-23, IL-1b, and IL-6, that were
expressed at higher levels by BpCyaA2 -treated MDDC. Instead,
the regulatory activity of IL-12p70, induced in MDDC in the
absence of active CyaA, may play a prominent role in inhibiting
Th17 polarization. This would be in agreement with studies
showing that IL-12p70 is detrimental for the expansion of Th17
cells [42]. Overall, the ex vivo polarization studies showed that
CyaA was ultimately responsible for enhancing Th17 and reducing
Th1 immunity induced by B. pertussis.
Figure 5. Analysis of MyD88-independent pathway induction.
MDDC were either untreated (none) or treated with BpWT or BpCyaA2.
Phosphorylation of IRF3 was determined at the indicated time-points by
Western blot. Data are from one representative out of three
independent experiments performed with MDDC obtained from
different donors.
doi:10.1371/journal.pone.0008734.g005
Figure6. Effects of kinase inhibition on Th polarization. A MDDC,
either untreated or treated with BpWT or BpCyaA2 in the absence or
presence of p38 inhibitor (SB203580), ERK1/2 inhibitor (PD98059) or PI3K
inhibitor (LY294002) for 48 h, were co-cultured with purified T cells. On
day 12, supernatants were collected and secreted cytokines were
measured by ELISA. Results of four independent experiments performed
with MDDC and T cells obtained from different donors are expressed as
the percent of change of cytokines (IFNc, IL-17 and IL-5) with respect to
the corresponding stimulus in the absence of inhibitors. Mean 6 SE of
cytokine production (pg/ml) in MDDC not treated with inhibitors was for
BpWT: IFNc=901361828; IL-17=900668; IL-5=71619; for BpCyaA2:
IFNc=983461225; IL-17=423694; IL-5=2165. * p,0.05 vs control,
calculated from the raw data.
doi:10.1371/journal.pone.0008734.g006
B.pertussis and Th1/Th17 Cells
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IL-10 production in mice [43] and to be involved in whole cell
vaccine-induced protection through Th1/Th17 induction [39].
Here we demonstrated a low intensity TLR4 and a strong TLR2
activation by B. pertussis (Figure 3). TLR4 engagement by B.
pertussis, although at low levels, was sufficient to activate the
MyD88-independent pathway, as testified by phosphorylation of
IRF3 (Figure 5), a link between TLR4 activation and the induction
of interferon inducible IRF1 and IRF8 necessary for MyD88-
independent IL-12p70 induction [44,45]. Both IRF3 phosphory-
lation and IRF1/IRF8 mRNA transcription were better promoted
by BpCyaA2 than BpWT indicating an inhibition of MyD88-
independent pathway by CyaA, that might represent a further
mechanisms adopted by B. pertussis to dampen the host immune
responses.
The use of MAPK inhibitors demonstrated a decisive role for
p38 in sustaining phenotypic maturation and cytokine production,
while ERK1/2 activity was involved in IL-12p70 production in
BpCyaA2 -treated MDDC (Figure 4B, C). Th1 induction, in the
form of IFNc production by BpWT -treated MDDC still occurred
after p38 inhibition (Figure 6), thus developing independently of
IL-12p70, which is no longer produced in these conditions
(Figure 4C). These data, together with the observation that BpWT
-treated MDDC promoted a Th1 expansion in the absence of IL-
12p70, indicated the presence of a non-canonical Th1 driving
signal induced by B. pertussis. The fact that inhibition of ERK1/2
pathway in MDDC resulted in significant decrease of IFNc
production by T cells (Figure 6), suggested that the Th1 driving
signal was dependent on ERK1/2 activity.
Thus, two different pathways appeared involved in the Th1
polarization. ERK1/2 signals might be responsible of IFNc
induction by BpWT -treated MDDC in the absence IL-12p70,
while in BpCyaA2 -treated MDDC p38-dependent IL-12p70
production enhances the Th1 profile.
Concerning Th17 polarization, it was dramatically reduced by
the p38 inhibitor (Figure 6). This result may reflect the strong
reduction of IL-1b and IL-23 production caused by p38 inhibition
in MDDC (Figure 4C).
ERK1/2 inhibition induced a significant increase of IL-17
production promoted by MDDC treated with BpCyaA2
(Figure 6), likely due to a sharp inhibition of IL-12p70 production
accompanied by a slight reduction of IL-23 and IL-1b in
BpCyaA2 -treated MDDC, suggesting a negative regulatory role
of IL-12p70 in the development of Th17 immunity [42].
Inhibition of PI3K activity in MDDC increased production of
IL-23 and IL-1b together with a concomitant reduction of IL-10,
suggesting an anti-inflammatory role of this kinase involved in the
regulation of innate responses to microbial pathogens [33].
However, PI3K inhibition did not cause appreciable changes in
Th polarization, apart from an increase in IL-5 levels with
BpCyaA2 -treated MDDC (Figure 6).
The fact that B. pertussis is able to potentiate the Th17 response,
even in the absence of CyaA, might be linked to the presence of
pertussis toxin. We have recently demonstrated that genetically
detoxified Pertussis toxin (dPT) -treated MDDC drive a mixed
Th1/Th17 polarization [41]. Like B. pertussis, dPT activates the
p38 and ERK1/2 pathways in MDDC, regulators of cytokine
expression, and the PI3K pathway, crucial in limiting IL-23 and
IL-1b and enhancing IL-10 production. A major difference from
the data reported here was in T cell polarization by dPT-treated
MDDC, where p38 inhibition markedly reduced the production of
IFNc by co-cultured T cells, reflecting the induction of the
canonical p38 -dependent and IL-12p70 -mediated Th1 polari-
zation. The differences observed in the activation pathway in
MDDC/T cells in B. pertussis and dPT are not surprising
considering the complexity of the interaction exerted by the
bacterium upon MDDC activation.
Previous observations have shown that B. pertussis and B.
bronchiseptica lacking CyaA caused a diminished inflammation
pathology in mice, due to a reduced ability to recruit leucocytes,
primarily neutrophils, suggesting that infiltrating cells are respon-
sible for lung injury [46,47]. It is now possible to re-interpret these
data in the light of the results of this study. Here we have shown
that CyaA ablation resulted in a reduced capacity to promote
expansion of IL-17 producing effectors, and it is well known that
the over-production of IL-17 fosters neutrophil recruitment to the
site of inflammation [48].
In the light of the results depicted here, it is possible to speculate
that CyaA mediates an escape strategy for the bacterium since it
reduces Th1 immunity and increases the Th17 responses thought
to be responsible, when the response is exacerbated, of enhanced
lung inflammation and injury.
Materials and Methods
Ethic Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All blood donors provided written
informed consent for the collection of samples and subsequent
analysis and the blood samples were processed anonymously. The
study was approved by the Review Board of the University La
Sapienza, Rome, Italy.
Reagents
Recombinant Bordetella pertussis CyaA and CyaA* were ex-
pressed and purified as described elsewhere [24,25]. Polymyxin B
and Brefeldin A were purchased from Sigma Chemicals (St. Louis,
MO). Purified E. coli LPS, synthetic bacterial lipoprotein S-[2,3-
bis(palmitoloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-
[S]-lysyl-[S]-lysyl-[S]-lysine X 3CF3COOH (Pam2CSK4), p44-
p42 ERK1/2 inhibitor PD98059, p38 MAPK inhibitor
SB203580, PI3K inhibitor LY294002 were from Cayla -
InvivoGen Europe (Toulouse, France). Human rGM-CSF and
rIL-4 were from R&D Systems (Minneapolis, MN). rIL-2 was
obtained from Roche (Basel, Switzerland). Fluorochrome-conju-
gated anti-human CD3, CD1a, CD14, CD38, CD80, CD83 and
appropriated mouse isotype-matched mAbs were from BD
Biosciences Europe (Erembodegem, Belgium). Rabbit polyclonal
IgG anti-p-p44/42 mitogen-activated protein kinases (MAPK)
(Thr202/Tyr204, ERK1/2), anti-p-p38 MAPK (Thr180/
Tyr182), anti-p-JNK/Stress Activated Protein Kinase (SAPK)
(Thr183/Tyr185), anti-p-I kappa B alpha (IkBa) (Ser32), anti-p-
IRF3 Ab were from Cell Signaling Technology, Inc. (Danvers,
MA). Mouse anti-b tubulin was from Invitrogen (Paisley, UK).
Bacterial Strains and Growth Conditions
B. pertussis strains: Bp18323 (BpWT) (ATCC reference strain 97-
97) and its isogenic Bp18HS19 mutant (BpCyaA2) [15,18] were
inoculated onto charcoal agar plates supplemented with 10% of
sheep blood (Oxoid, Basingstoke, UK) and grown at 37uC for 72 h
to visualize hemolysis and plated again on charcoal agar for 48 h
at 37uC. Bacteria were then collected and re-suspended in 5 ml of
phosphate buffered saline (PBS). Bacterial concentration was
estimated by measuring the optical density at 600 nm and the
suspension adjusted to a final concentration of 10
9 CFU/ml. The
bacterial concentration was then checked retrospectively by CFU
evaluation of the final bacteria suspension.
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Human monocytes were purified from peripheral blood of
healthy blood donors (Courtesy of Dr. Ferrazza, ‘‘Centro
Trasfusionale Policlinico Umberto I’’, University La Sapienza,
Rome, Italy) and cultured in RPMI 1640 (GIBCO, Invitrogen),
supplemented with heat-inactivated 10% LPS-screened FCS,
1 mM sodium pyruvate, 0.1 mM nonessential amino acids,
2 mM L-glutamine, 25 mM HEPES (N-2-hydroxyethylpiprazin-
N’-2-ethansulfonic acid), 100 U/ml penicillin, 100 mg/ml strep-
tomycin, all from Hyclone Laboratories and 0.05 mM 2-ME
(Sigma) (hereafter defined as complete medium) in the presence of
GM-CSF (25 ng/ml) and IL-4 (25 ng/ml). After 6 days, immature
MDDC were washed and analyzed by cytofluorometric analysis
for CD1a, CD14 and CD38 expression. Where indicated, MDDC
were treated with ERK1/2 inhibitor PD98059 (100 mM), p38
inhibitor SB203580 (20 mM) or PI3K inhibitor LY294002 (5 mM)
for 1 h prior to B. pertussis treatment. E. coli LPS (100 ng/ml) was
used as positive stimulus to induce MDDC maturation.
MDDC (10
6 cell/ml) were re-suspended in complete medium
without penicillin and streptomycin (hereafter defined as Bp
medium), and treated with B. pertussis cells as described elsewhere
[23]. After 2h, cells were extensively washed in the presence of
polymyxin B (5 mg/ml) and incubated at 37uC, 5% CO2 for 48 h
in Bp medium with 100 U/ml penicillin and 100 mg/ml
streptomycin added. In a previous study we tested several
bacterium-to-cell ratios, and the 100:1 was chosen as optimal
ratio on the basis of bacterial ability to induce MDDC maturation
without affecting viability [23].
Where indicated, recombinant CyaA (50 ng/ml) or CyaA*
(50 ng/ml) was added at optimal dosage (determined in prelim-
inary experiments) to MDDC cultures, alone or immediately after
BpCyaA2 treatment.
After 48 h, treated MDDC were harvested for immunopheno-
typic analysis and supernatants for cytokine measurement by
ELISA.
Cell Lines
Human epithelial kidney (HEK)-293 cells stably transfected
with human TLR4, MD2 and CD14 (HEK/TLR4) or human
TLR2 (HEK/TLR2) were purchased from InvivoGen; The
HEK/TLR clones were grown in standard Dulbecco’s modified
Eagle’s medium (DMEM) (GIBCO, Invitrogen) with heat-
inactivated 10% LPS-screened fetal calf serum (FCS)
(LAL,1 ng/ml LPS) supplemented with 1 mM sodium pyruvate,
0.1 mM non-essential amino acids, 2 mM L-glutamine, all from
Hyclone Laboratories (Logan, OH), and normocin
TM (100 mg/ml,
InvivoGen), in a 5% saturated CO2 atmosphere at 37uC. HEK/
TLR4 culture medium was supplemented with 0.2 mM Blasticidin
(InvivoGen) and HygroGold
TM (50 mg/ml, InvivoGen). HEK/
TLR2 culture medium was supplemented with 0.6 mM G418
Sulfate (InvivoGen). HEK293/TLR cells were transfected with a
plasmid encoding secreted alkaline phosphatase (SEAP) (pNifty2-
SEAP, InvivoGen) as previously described [31].
TLR Signaling Assay
The induction of TLR signaling in HEK/TLR/p-Nifty2-SEAP
clones was assessed by measuring SEAP activity using QUANTI-
Blue
TM colorimetric assay (InvivoGen). Briefly, HEK/TLR/p-
Nifty2-SEAP cells with specific antibiotics added, as specified
before, were seeded into 24-well plates at a density of 2610
5 cells
in 0.5 ml HEK medium per well for 48 h and then cells were
either untreated (none), treated for 16 h with B. pertussis at 100:1
bacterium-cell ratio (the optimal ratio to induce maximal TLR4 or
TLR2 signaling without affecting cell viability), ultrapure LPS
from E. coli or Pam2CSK4. Supernatants (10 ml) were then
transferred to a 96-well plate and incubated at 37uC with
QUANTI-Blue
TM (200 ml). SEAP activity was measured by
reading optical density at 655 nm with a 3550-UV Microplate
Reader (BioRad, Philadelphia, PA). Data are reported as the fold
induction of SEAP activity over untreated controls.
Isolation and Polarization of T Lymphocytes
T cells were purified from peripheral blood mononuclear cells by
negativesortingwithmagneticbeads(PanT-cellKit,MilteniyBiotec,
Auburn, CA). Purity of cell preparations was assessed by cytofluoro-
metric staining [23]. T cells (0.5610
6) were cultured in complete
medium in 24-well plates (Costar) in the presence of MDDC
(0.5610
5). On day 5, IL-2 (50 U/ml) was added to the cultures. On
day 12, supernatants were harvested for cytokine measurement.
Immunophenotypic Analysis
Cells were washed and re-suspended in PBS containing 3% FBS
and 0.09% NaN3, then incubated with a panel of fluorochrome-
conjugated mAbs (obtained from BD Biosciences, San Jose, CA)
specific for MDDC: anti-CD14, CD1a, CD80, CD83 and CD38;
or specific for T cells: anti-CD3. Isotype-matched antibodies were
used as negative control. Cells were analyzed with a FACScan (BD
Biosciences). Fluorescence data are reported as percentage of
positive cells when treatment induces the expression of the marker
in cells that were negative; median fluorescence intensity (MFI)
was used when treatment increased the expression of the marker in
cells that were already positive.
Determination of Cytokine Levels by ELISA
To measure cytokine production, MDDC were cultured in the
presence of the indicated stimuli in 12 ml tubes (Falcon, Becton
Dickinson, Lincoln Park, NJ) at 37uC, 5% CO2. Supernatants were
collected after 48 h, and IL-10, IL-12p70, IL-23, IL-1b and IL-6
production was assessed by ELISA (Quantikine, R&D Systems,
Minneapolis, MN) and IL-23 by Bender MedSystem (Burlingame,
CA) with a sensitivity of 1.0 pg/ml for IL-1b, 0.7 pg/ml for IL-6,
3.9 pg/ml for IL-10, 5.0 pg/ml for IL-12p70 and 20.0 pg/ml for
IL-23. Optical density obtained was measured with a 3550-UV
Microplate Reader (BioRad Philadelphia, PA) at 450 nm.
Cytokines in the supernatants from polarized T cells were
assayed by ELISA specific for IFNc, IL-5 and IL-17 (Quantikine,
R&D Systems). The lower detection limits were 8.0 pg/ml for
IFNc, 3.0 pg/ml for IL-5, 15.0 pg/ml for IL-17.
mRNA Cytokine Expression by TaqMan Real-Time
Reverse Transcriptase-PCR Aanalysis
To measure cytokine mRNA expression, TaqMan Real-time
Reverse Transcriptase-PCR (RT-PCR) analysis was used (Applied
biosystems, Foster City, CA). Total RNA was extracted from
MDDC at different time points and reverse transcription was
carried out as previously described [15]. TaqMan assays were
performed according to manufacturer’s instructions with an ABI
7700 thermocycler (Applied biosystems). PCR was performed,
amplifying the target cDNA (IRF1 and IRF8) transcripts and the
b-actin cDNA as endogenous control. Data obtained were
analyzed with PE Relative Quantification software of Applied
Biosystems. Specific mRNA transcript levels were expressed as fold
increase compared to basal conditions.
Western Blot Analysis
MDDC were starved by culturing overnight in culture medium
supplemented with 1% LPS-screened FCS. Cells were then
B.pertussis and Th1/Th17 Cells
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RIPA buffer as previously described [40]. Immunoreactive protein
was detected by incubating blots with anti-phosphorylated proteins
(or anti-unphosphorylated b-tubulin as control) overnight at 4uC.
Blots were washed in Tris-buffered saline 0.1% Tween-20,
incubated with horse-radish-peroxidase (HRP)-conjugated goat
anti-rabbit IgG (Bio-Rad Laboratories, Hercules, CA) (to reveal
phosphorylated proteins) or HRP-conjugated goat anti-mouse IgG
(GE Healthcare) (to reveal control proteins) developed with the
enhanced chemiluminescence (ECL) reagents from Pierce
(Rockford, IL).
Statistical Analysis
Statistical descriptive analyses were carried out using the SPSS
Inc (Chicago, IL) statistical package. Differences between mean
values were assessed by two-tailed Student’s t test and were
statistically significant for P values ,0.05.
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